CD19 and neoplasm: Studies with dual CAR-T cells containing distinct CAR molecules with anti-HER2 scFv-CD28-CD3z (HER2 scFv-CD28-CD3z) and IL13Rα2 scFv-CD28-CD3z, or CD19 scFv-41BB-CD3z and CD123 scFv-41BB-CD3z, or CD19 scFv-OX40-CD3z and CD22 scFv-41BB-CD3z showed enhanced anti-tumor efficacy [94,95].